New therapies in acute decompensated heart failure

Current Opinion in Cardiology

Volumn 23, Issue 2, 2008, Pages 134-140

  Gauthier, Nadine ^a   Anselm, Anjali H ^a   Haddad, Haissam ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Acute decompensated heart failure; Cardiac sensitizers; Novel therapies; Vasoactive therapies; Vasopressin antagonists

Indexed keywords

DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LEVOSIMENDAN; LOOP DIURETIC AGENT; METOLAZONE; MILRINONE; NESIRITIDE; NITRIC ACID DERIVATIVE; PLACEBO; TOLVAPTAN; VASOPRESSIN;

ARTIFICIAL VENTILATION; CARDIOGENIC SHOCK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DIURESIS; DRUG MEGADOSE; DYSPNEA; FLUID BALANCE; HAZARD RATIO; HEALTH HAZARD; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPOTENSION; LOW DRUG DOSE; LUNG CONGESTION; LUNG EDEMA; META ANALYSIS; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; ULTRAFILTRATION; VASOCONSTRICTION; WEIGHT REDUCTION;

ACUTE DISEASE; AGED; HEART FAILURE; HUMANS;

EID: 40049085404     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282f798be     Document Type: Review

References (55)

1. Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005; 96 (6A):5G-10G.
2. Earl GL, Fitzpatrick JT. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure. Ann Pharmacother 2005; 39:1888-1896.
3. Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol 2005; 96 (suppl): 32G-40G.
4. Felker GM, Adams KF. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 2003; 145:S18-S25.
5. Stough WG, O'Connor CM, Gheorghiade M. Overview of current noninodilator therapies for acute heart failure syndromes. Am J Cardiol 2005; 96 (suppl):41G-46G.
6. Adams KF, Fonarow GC, Emerman CL. Characteristics and outcomes of patients hospitalized for heart failure in the United States, ADHERE. Am Heart J 2005; 149:209-216.
7. Gheorghiade M, Mebazaa A. Introduction to acute heart failure syndromes. Am J Cardiol 2005; 96 (6A):1G-4G.
8. Gheorghiade M, Mebazaa A. The challenge of acute heart failure syndromes. Am J Cardiol 2005; 96 (6A):86G-89G.
9. Perna ER, Macin SM, Parras JI. Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J 2002; 143:814-820.
10. deGoma EM, Vagelos RH. Emerging therapies for the management of decompensated heart failure. J Am Coll Cardiol 2006; 48:2397-2409.
11. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341:577-585.
12. Stevenson LW. Are hemodynamic goals viable in tailoring heart failure therapy? Circulation 2006; 113:1020-1033.
13. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005; 26: 384-416.
14. Arnold JMO, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23-45.
15. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary edema. Lancet 1998; 351: 389-393.
16. De Bruyne LKM. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J 2003; 79:268-271.
17. Ravnan SL, Ravnan MC, Deedwania PC. Diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Failure 2002; 8:80-85.
18. Kramer BK, Schweda F, Gunter AJ. Diuretic treatment and diuretic resistance in heart failure. Am J Med 1999; 106:90-96.
19. Salvador DR, Rey NR, Ramos GC, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005; 3:CD003178
20. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105:1348-1353.
21. Gottlieb SS, Skettino SL, Wolff A, et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000; 35:56-59.
22. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46:1785-1791.
23. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure. J Am Med Assoc 2007; 297:1319-1374. This large randomized trial shows the symptom relief and weight reduction associated with Tolvaptan, a vasopressin antagonist, a novel vasoactive drug for the treatment of congestive acute heart failure.
24. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral Tolvaptan in patients hospitalized for worsening heart failure, the EVEREST Outcome Trial. J Am Med Assoc 2007; 297:1319-1331. This large randomized trial looks at long-term clinical benefits of Tolvaptan that showed symptomatic relief in the hospitalized heart-failure patient. No mortality benefit was associated with Tolvaptan therapy in the acute setting.
25. Gheorghiade M, Gattis WA, O'Connor CM, Kirkwood F. Effects of Tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). J Am Med Assoc 2004; 291:1963-1971.
26. Burrell LM, Phillips PA, Rolls KA. Vascular responses to vasopressin antagonists in man and rat. Clin Sci (Lond) 1994; 87:389-395.
27. Felker GM, Benza RL, Bleakley Chandler A, et al. Heart failure etiology and response to milrinone in decompensated heart failure. Results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41:997-1003.
28. Echols MR, Mahaffey KW, Banerjee A, et al. Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from OPTIME-CHF Trial. J Cardiac Failure 2006; 12:684-688.
29. He FJ, Markandu ND, Sagnella GA, et al. Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 1998; 32:B20-B24.
30. Taylor AL, Ziesche S, Yancy C. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049-2057.
31. Allen LA, O'Connor CM. Management of acute decompensated heart failure. Can Med Assoc J 2007; 176:797-805.
32. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002; 39:798-803.
33. Kurien S, Warfield KT, Wood CM, Miller WL. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes on renal function and mortality in patients treated with nesiritide. Am J Cardiol 2006; 98:1627-1630.
34. Vasodilation in the Management of Acute CHF (VMAC) Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure. J Am Med Assoc 2002; 287:1531-1540.
35. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with Nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111:1487-1491.
36. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with Nesiritide for decompensated heart failure. J Am Med Assoc 2005; 293:1900-1905.
37. Hauptman PJ, Schnitzler MA, Swindle J, et al. Use of Nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. J Am Med Assoc 2006; 296:1877-1884.
38. Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure. Eur J Heart Failure 2002; 4:515-529.
39. Bayram M, De Luca L, Massie MB, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005; 96 (suppl):47G-58G.
40. Freimark D, Feinberg MS, Matezky S, et al. Impact of short-term intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure. Am Heart J 2004; 148:878-882.
41. Elkayam U, Tasissa G, Binanay C, Stevenson L. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007; 153:98-104.
42. Cuffe MS, Califf RM, Adams KF. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. Am J Med 2002; 287:1541-1547.
43. Greenberg B, Borghi C, Perrone S. Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitizer, Levosimendan? Eur J Heart Failure 2003; 5:13-21.
44. Flevari P, Parissis J, Leftheriotis D, et al. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 2006; 98:1641-1645.
45. Follath F, Franco F, Silva Cardoso J. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 2005; 96 (suppl):80G-85G.
46. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intervenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double blind trial. Lancet 2003; 360:196-202.
47. Cleland JGF, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS, and cardiac resynchronisation therapy in heart failure. Eur J Heart Failure 2004; 6:501-508.
48. Packer M. Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy (REVIVE II) study [abstract]. Am Heart Sci Sessions 2005.
49. Mebazaa A. Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure. Crit Care 2004; 8 (suppl):87.
50. Mebazaa A. The SURVIVE-W Trial: comparison of dobutamine and levosimendan on survival in acute decompensated heart failure [abstract]. Am Heart Sci Sessions 2005.
51. Maytin M, Colucci WS. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005; 96 (suppl):26G-31G.
52. Masip J, Betbese AJ. Noninvasive pressure support ventilation vs. conventional oxygen therapy in acute cardiogenic pulmonary edema: a randomized trial. Lancet 2000; 356:2126-2132.
53. Sharma A, Herman DD, Mehta RL. Clinical benefit and approach of ultra-filtration in acute heart failure. Cardiology 2001; 96:144-154.
54. Ronco C, Ricci Z, Bellomo R, Bedogni F. Extracorporeal ultrafiltration for the treatment of overhydration and congestive heart failure. Cardiology 2001; 96:155-168.
55. Costanzo MR, Guglin M, Saltzberg M, et al. UNLOAD Trial Investigators, ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49:675-683.